ATRA — Atara Biotherapeutics Cashflow Statement
0.000.00%
HealthcareSpeculativeMid CapMomentum Trap
- $457.32m
- $196.51m
- $20.34m
Annual cashflow statement for Atara Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -119 | -231 | -291 | -307 | -340 |
Depreciation | |||||
Non-Cash Items | 23.8 | 32.2 | 52.4 | 53.8 | 57.7 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 7.2 | 15 | -4.15 | 63.7 | 52.6 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -87.5 | -180 | -236 | -181 | -221 |
Capital Expenditures | -20.2 | -35.9 | -5.73 | -4.51 | -10.6 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 120 | -160 | 66.2 | -116 | 32.8 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 99.9 | -196 | 60.5 | -121 | 22.3 |
Financing Cash Flow Items | 0.892 | 17.2 | 0.655 | 4.99 | 5.5 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 20 | 358 | 189 | 428 | 104 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 32.5 | -18.5 | 13.6 | 126 | -94.3 |